Related Experiment Video

Updated: Apr 21, 2026

High Resolution Electron Microscopy of the Helicobacter pylori Cag Type IV Secretion System Pili Produced in Varying Conditions of Iron Availability
09:05

High Resolution Electron Microscopy of the Helicobacter pylori Cag Type IV Secretion System Pili Produced in Varying Conditions of Iron Availability

Published on: November 21, 2014

16.2K

KaiWei JianPI Ointment Downregulates Fcgbp and Modulates HMGB1/TLR4 Signaling to Combat Ferroptosis in H. pylori

Xiaoying Zhu1,2, Jie Liu2, Meng Chen1,2

  • 1Shenzhen Clinical College of Integrated Chinese and Western Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China, gzucm.edu.cn.

The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale
|April 20, 2026
PubMed
Abstract

Insights

KaiWei JianPI Ointment may treat H. pylori infection by inhibiting ferroptosis via the HMGB1/TLR4 pathway. This traditional Chinese medicine offers a novel therapeutic approach for H. pylori eradication.

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Immunology

Background:

  • Helicobacter pylori infection is a global health concern.
  • Traditional Chinese Medicine (TCM) offers potential therapeutic avenues.
  • Understanding the molecular mechanisms of TCM is crucial for modern applications.

Purpose of the Study:

  • To investigate the therapeutic mechanisms of KaiWei JianPI Ointment against H. pylori infection.
  • To explore the role of ferroptosis and the HMGB1/TLR4 signaling pathway.
  • To identify active components and their targets within the ointment.

Main Methods:

  • Network pharmacology and molecular docking were employed.
  • Transcriptome sequencing analyzed gene expression changes in rat gastric tissues.
  • Molecular biology techniques assessed ferroptosis markers (Fe2+, MDA) and signaling pathways.

Main Results:

  • Identified 152 active components and 76 differentially expressed genes related to immune responses.
  • KaiWei JianPI Ointment treatment reduced Fe2+ and MDA levels, indicating ferroptosis inhibition.
  • Observed downregulation of Fcgbp and modulation of the HMGB1/TLR4 signaling pathway.

Conclusions:

  • KaiWei JianPI Ointment demonstrates potential for treating H. pylori infection by inhibiting ferroptosis via the HMGB1/TLR4 pathway.
  • This study bridges TCM principles with modern therapeutic strategies.
  • Further clinical validation is recommended to explore underlying mechanisms.
Keywords:
FcgbpH. pylori infectionKaiWei JianPI ointmentTLR4/HMGB1ferroptosis

More Related Videos

Mouse Models Of Helicobacter Infection And Gastric Pathologies07:43

Mouse Models Of Helicobacter Infection And Gastric Pathologies

Published on: October 18, 2018

23.6K
Expression, Purification, and Antimicrobial Activity of S100A1211:10

Expression, Purification, and Antimicrobial Activity of S100A12

Published on: May 13, 2017

9.0K

Related Concept Videos

Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
17
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.4K
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
23
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.3K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.6K
Export of Misfolded Proteins out of the ER01:32

Export of Misfolded Proteins out of the ER

After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
5.7K